DHPLC screening of cystic fibrosis gene mutations
- PMID: 11933191
- DOI: 10.1002/humu.10065
DHPLC screening of cystic fibrosis gene mutations
Abstract
Denaturing high performance liquid chromatography (DHPLC) using ion-pairing reverse phase chromatography (IPRPC) columns is a technique for the screening of gene mutations. In order to evaluate the potential utility of this assay method in a clinical laboratory setting, we subjected the PCR products of 73 CF patients known to bear CFTR mutations to this analytic technique. We used thermal denaturation profile parameters specified by the MELT program tool, made available by Stanford University. Using this strategy, we determined an initial analytic sensitivity of 90.4% for any of 73 known CFTR mutations. Most of the mutations not detected by DHPLC under these conditions are alpha-substitutions. This information may eventually help to improve the MELT algorithm. Increasing column denaturation temperatures for one or two degrees above those recommended by the MELT program allowed 100% detection of CFTR mutations tested. By comparing DHPLC methodology used in this study with the recently reported study based on Wavemaker 3.4.4 software (Transgenomic, Omaha, NE) [Le Marechal et al., 2001) and with previous SSCP analysis of CFTR mutations [Ravnik-Glavac et al., 1994] we emphasized differences and similarities in order to refine the DHPLC system and discuss the relationship to the alternative approaches. We conclude that the DHPLC method, under optimized conditions, is highly accurate, rapid, and efficient in detecting mutations in the CFTR gene and may find high utility in screening individuals for CFTR mutations. Hum Mutat 19:374-383, 2002. Published 2002 Wiley-Liss, Inc.
Similar articles
-
Molecular analysis using DHPLC of cystic fibrosis: increase of the mutation detection rate among the affected population in Central Italy.BMC Med Genet. 2004 Apr 14;5:8. doi: 10.1186/1471-2350-5-8. BMC Med Genet. 2004. PMID: 15084222 Free PMC article.
-
NF1 gene analysis based on DHPLC.Hum Mutat. 2003 Feb;21(2):171-2. doi: 10.1002/humu.9111. Hum Mutat. 2003. PMID: 12552569
-
A comparison of high-resolution melting analysis with denaturing high-performance liquid chromatography for mutation scanning: cystic fibrosis transmembrane conductance regulator gene as a model.Am J Clin Pathol. 2005 Sep;124(3):330-8. doi: 10.1309/BF3M-LJN8-J527-MWQY. Am J Clin Pathol. 2005. PMID: 16191501
-
Analysis of genomic CFTR DNA.J Cyst Fibros. 2004 Aug;3 Suppl 2:7-10. doi: 10.1016/j.jcf.2004.05.003. J Cyst Fibros. 2004. PMID: 15463917 Review.
-
[Cystic fibrosis transmembrane conductance regulator (CFTR) gene: mutations and clinical phenotypes].Ugeskr Laeger. 2003 Feb 24;165(9):912-6. Ugeskr Laeger. 2003. PMID: 12661515 Review. Danish.
Cited by
-
A haplotype framework for cystic fibrosis mutations in Iran.J Mol Diagn. 2006 Feb;8(1):119-27. doi: 10.2353/jmoldx.2006.050063. J Mol Diagn. 2006. PMID: 16436643 Free PMC article.
-
Variation in conserved non-coding sequences on chromosome 5q and susceptibility to asthma and atopy.Respir Res. 2005 Dec 10;6(1):145. doi: 10.1186/1465-9921-6-145. Respir Res. 2005. PMID: 16336695 Free PMC article. Clinical Trial.
-
Prenatal screening of Cystic Fibrosis: a single centre experience.J Prenat Med. 2008 Jan;2(1):6-10. J Prenat Med. 2008. PMID: 22439019 Free PMC article.
-
A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes.BMC Cancer. 2011 Jun 24;11:265. doi: 10.1186/1471-2407-11-265. BMC Cancer. 2011. PMID: 21702907 Free PMC article.
-
Molecular analysis using DHPLC of cystic fibrosis: increase of the mutation detection rate among the affected population in Central Italy.BMC Med Genet. 2004 Apr 14;5:8. doi: 10.1186/1471-2350-5-8. BMC Med Genet. 2004. PMID: 15084222 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical